Schizophrenia

New England Journal of Medicine

Volumn 334, Issue 1, 1996, Pages 34-41

  Kane, John Michael ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; CENTRAL NERVOUS SYSTEM AGENTS;

CLINICAL FEATURE; DIAGNOSTIC ACCURACY; HUMAN; HYPOTHESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; DELAYED RELEASE FORMULATION;

ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; SCHIZOPHRENIA;

EID: 0030568166     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/nejm199601043340109     Document Type: Review

References (97)

1. Kendler KS, Diehl SR. The genetics of schizophrenia: a current, genetic-epidemiologic perspective Schizophr Bull 1993;19:261-85
2. Kirch DG. Infection and autoimmunity as etiologic factors in schizophrenia a review and reappraisal. Schizophr Bull 1993;19:355-70.
3. Seeman P, Niznik HB Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1990;4:2737-44.
4. 4. Neuropsychopharmacology 1992,7:261-84
5. Anden N-E, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics Eur J Pharmacol 1970;11:303-14
6. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192:481-3.
7. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors Nature 1976;261:717-9
8. Lieberman JA, Kane JM, Alvir J Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91:415-33.
9. 2 dopamine receptors in drug-naive schizophrenics Science 1986;234 1558-63 [Erratum, Science 1987;235 623.]
10. 2-dopamine receptor binding examined in vivo by PET Acta Psychiatr Scand Suppl 1990,358 67-71.
11. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96
12. Klein DF, Davis JM. Diagnosis and drug treatment of psychiatric disorders Baltimore: Williams & Wilkins, 1969
13. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr Principles and practice of psychopharmacotherapy Baltimore. Williams & Wilkins, 1993:104-6.
14. Goldberg SC, Frosch WA, Drossman AK, Schooler NR, Johnson GF. Prediction of response to phenothiazines in schizophrenia: a crossvalidation study Arch Gen Psychiatry 1972;26:367-73
15. Bailine SH, Lesser MS, Krubit G, Ravasz TJ, Davis RA, Kane JM. Comparison of IM haloperidol and IM chlorpromazine in the treatment of acutely psychotic patients Psychiatr Hosp 1987;18:127-9.
16. Heinrich K, Klieser E, Lehmann E, Kinzlei E, Hruschka H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 1994;18 129-37.
17. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia Psychopharmacol Bull 1992;28:213-8.
18. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992,85:295-305.
19. Muller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol 1992;15:Suppl 1:90A-91A.
20. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40. [Erratum, J Clin Psychopharmacol 1993;13:149.]
21. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993;26:121-4.
22. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia Am J Psychiatry 1994;151:825-35
23. Fitton A, Heel RC Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990;40:722-47.
24. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-7.
25. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991;17:217-45.
26. Mallya AR, Roos PD, Roebuck-Colgan K. Restraint, seclusion, and clozapine J Clin Psychiatry 1992,53:395-7
27. Meltzer HY, Okayli G Reduction of suicidality during clozapine treatment in neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-90
28. Quitkin F, Rifkin A, Klein DF. Very high dosage vs standard dosage fluphenazine in schizophrenia: a double-blind study of nonchronic treatment-refractory patients. Arch Gen Psychiatry 1975;32:1276-81.
29. Ericksen SE, Hurt SW, Chang S. Haloperidol dose, plasma levels, and clinical response a double-blind study. Psychopharmacol Bull 1978,14 15-6.
30. Neborsky R, Janowsky D, Munson E, Depry D Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol: behavior considerations. Arch Gen Psychiatry 1981,38:195-9.
31. McCreadie RG, MacDonald IM. High dosage haloperidol in chronic schizophrenia. Br J Psychiatry 1977;131:310-6.
32. Bjorndal N, Bjerre M, Gerlach J, et al High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin Psychopharmacology (Berl) 1980;67:17-23.
33. Kinon BJ, Kane JM, Johns C, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993,29:309-14.
34. Reardon GT, Rifkin A, Schwartz A, Myerson A, Siris SG. Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry 1989;146 726-9.
35. Remington G, Pollock B, Voineskos G, Reed K, Coulter K. Acutely psychotic patients receiving high-dose haloperidol therapy. J Clin Psychopharmacol 1993,13:41-5.
36. Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M Dosage of haloperidol for schizophrenia Arch Gen Psychiatry 1991;48:166-70.
37. Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990;47:761-8.
38. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754-8
39. Volavka J, Cooper T, Czobor P, et al Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 1992;49:354-61.
40. Davis JM, Barter JT, Kane JM. Antipsychotic drugs In: Kaplan HI, Sadock BJ, eds Comprehensive textbook of psychiatry/V. 5th ed Vol. 2. Baltimore: Williams & Wilkins, 1989:1591-626.
41. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49 538-44
42. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;146:905-8.
43. 2-dopamine receptor occupancy in relation to antipsychotic drug effects, a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
44. The American Psychiatric Association Task Force on Tardive Dyskinesia. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, D.C.. American Psychiatric Association, 1992.
45. Rifkin A, Quitkin F, Kane J, Struve F, Klein DF Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal Arch Gen Psychiatry 1978;35:483-9.
46. Gratz SS, Levinson DF, Simpson GM. Neuroleptic malignant syndrome. In. Kane JM, Lieberman JA, eds. Adverse effects of psychotropic drugs New York Guilford Press, 1992:266-84.
47. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990;47:945-8.
48. Devinsky O, Pacia SV Seizures during clozapine therapy. J Clin Psychiatry 1994;55:Suppl B:153-6.
49. Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992;53:439-42.
50. Casey DE Clozapine: neuroleptic-induced EPS and tardive dyskinesia Psychopharmacology (Berl) 1989;99:Suppl:S47-S53.
51. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327-30.
52. Glazer WM, Kane JM. Depot neuroleptic therapy an underutilized treatment option. J Clin Psychiatry 1992;53:426-33
53. Hirschowitz J, Casper R, Garver DL, Chang S. Lithium response in good prognosis schizophrenia. Am J Psychiatry 1980;137:916-20.
54. Small JG, Kellams JJ, Milstein V, Moore J A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975;132:1315-7.
55. Growe GA, Crayton JW, Klass DB, Evans H, Strizich M. Lithium in chronic schizophrenia. Am J Psychiatry 1979;136:454-5.
56. Carman JS, Bigelow LB, Wyatt RJ Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients J Clin Psychiatry 1981; 42:124-8
57. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991;148:714-26.
58. Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior J Clin Psychiatry 1991;52:177-80.
59. Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989;146:1598-601
60. Arana GW, Ornsteen ML, Kanter S, Friedman HL, Greenblatt DJ, Shader RI. The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. Psychopharmacol Bull 1986;22 77-87.
61. Barbee JG, Mancuso DM, Freed CR, Todorov AA. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry 1992;149:506-10. [Erratum, Am J Psychiatry 1992,149:1129.]
62. Pato CN, Wolkowitz OM, Rapaport M, Schulz SC, Pickar D. Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia Psychopharmacol Bull 1989;25:263-6
63. Hanlon TE, Ota KY, Kurland AA. Comparative effects of fluphenazine. fluphenazine-chlordiazepoxide and fluphenazine-imipramine Dis Nerv Syst 1970,31:171-7.
64. Wolkowitz OM, Breier A, Doran A, et al. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients: preliminary results. Arch Gen Psychiatry 1988;45:664-71
65. Csernansky JG, Rincy SJ, Lombrozo L, Overall JE, Hollister LE. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms Arch Gen Psychiatry 1988;45:655-9.
66. Menza MA, Harris D. Benzodiazepines and catatonia. an overview. Biol Psychiatry 1989;26:842-6.
67. Meltzer HY. New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 1993,16:365-85.
68. Post RM Non-lithium treatment for bipolar disorder. J Clin Psychiatry 1990;51:Suppl:9-16
69. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992;149:108-11.
70. Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenia and schizoaffective psychosis: a review. J Psychiatry Neurosci 1992;17:1-14.
71. Schulz SC, Kahn EM, Baker RW, Conley RR. Lithium and carbamazepine augmentation in treatment-refractory schizophrenia In: Angrist B, Schulz SC, eds. The neuroleptic-nonresponsive patient: characterization and treatment. Washington, D.C.: American Psychiatric Press, 1990:109-36
72. Carpenter WT Jr, Kurz R, Kirkpatrick B, et al Carbamazepine maintenance treatment m outpatient schizophrenics. Arch Gen Psychiatry 1991;48 69-72
73. Siris SG, van Kammen DP, Docherty JP. The use of antidepressant drugs in schizophrenia: a review of the literature. Arch Gen Psychiatry 1978;35 1368-77.
74. Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial. Arch Gen Psychiatry 1987,44:533-9
75. Prusoff BA, Williams DH, Weissman MM, Astrachan BM. Treatment of secondary depression in schizophrenia a double-blind, placebo-controlled trial of amitriptyline added to perphenazine Arch Gen Psychiatry 1979;36: 569-75.
76. Siris SG, Cutler J, Owen K, Mason S, Gingerich S, Lang MP Adjunctive imipramine maintenance treatment in schizophrenic patients with remitted postpsychotic depression Am J Psychiatry 1989;146:1495-7.
77. Chien CP, Dimascio A, Cole JO. Antiparkinsonian agents and depot phenothiazine. Am J Psychiatry 1974,131:86-90.
78. Hanlon TE, Schoenrich C, Freinek W, Turek I, Kurland AA. Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients. Psychopharmacologia 1966,9:328-39.
79. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes Arch Gen Psychiatry 1983;40:1113-7
80. Davis JM. Overview: maintenance therapy in psychiatry. I. Schizophrenia. Am J Psychiatry 1975;132:1237-45.
81. Kane JM, Lieberman JA. Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY, ed. Psychopharmacology. the third generation of progress. New York: Raven Press, 1987:1103-9.
82. Kane JM. Treatment of schizophrenia. Schizophr Bull 1987;13:133-56
83. Kissling W, ed. Guidelines for neuroleptic relapse prevention in schizophrenia Berlin, Germany: Springer-Verlag, 1991.
84. Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs: place in therapy. Drugs 1994;47 741-73. [Erratum, Drugs 1994,48 616.]
85. Kane JM, Rikfin A, Woerner MG, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 1983;40:893-6.
86. Kane JM, Woerner MG, Sarantakos S. Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens J Clin Psychiatry 1986;47:Suppl.30-3
87. Marder SR, Van Putten T, Mintz J, et al Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984;41:1025-9.
88. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR Low-and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987;44:518-21.
89. Johnson DA, Ludlow JM, Street K, Taylor RD Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia Br J Psychiatry 1987,151:634-8
90. Hogarty GE, McEvoy JP, Munetz M, et al Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: results in a two-year controlled study Arch Gen Psychiatry 1988;45:797-805
91. Kane JM, Davis JM, Schooler NR, Marder SR, Brauzer B, Casey DE. A one-year comparison of four dosages of haloperidol decanoate. Schizophr Res 1993;9:239-40. abstract.
92. Schooler NR, Keith SJ, Severe JB, Mathews SM Treatment strategies in schizophrenia: effects of dosage reduction and family management outcome. Schizophr Res 1993,9:260. abstract.
93. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138-48. [Erratum, Am J Psychiatry 1991;148:819]
94. Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia: two-year results Arch Gen Psychiatry 1991;48:333-9.
95. Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ 1989;298:985-90.
96. Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990,301:837-42.
97. Pietzcker A, Gaebel W, Kopeke W, et al Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study J Psychiatr Res 1993;27:321-39.